Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing – STAT

Business News

  1. Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing  STAT
  2. Monthly weight loss drug helps people lose 20% of body weight, trial finds  NBC News
  3. Amgen Shares Fall on Weight-Loss Drug Tummy Troubles  Barron’s
  4. ADA25: Tweaked dosing schedule for MariTide cuts vomiting rates nearly in half  FirstWord Pharma
  5. RESULTS FROM AMGEN’S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS  PR Newswire

Source: Business News

/by